SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high has fueled buyout speculationoften centered on Sanofiand hopes for a short squeeze, with traders also pointing to heavy call-option activity. BRIUMVIs commercial growth and forthcoming earnings and subcutaneous data add to the optimism, while some traders doubt a deal is imminent and see the rally as momentum ahead of results.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,589,443 with 63,351,197,653 in circulation. The last known price of XRP is 1.24455819 USD and is down -0.63 over the last 24 hours. It is currently trading on 1893 active market(s) with $917,900,293.08 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is under pressure amid a broader crypto selloff linked by traders to the Binance hack, while Ripples Swell announcements have drawn disappointment over the tokens muted response. The main debate is whether Ripples partnerships, bank charter and RLUSD growth will create demand for XRP, or primarily benefit Ripple and its stablecoin instead.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the dominant focus, with traders debating whether strong results and raised guidance can clear an already high bar as AI stocks face a broader pullback. Bulls expect continued growth, while skeptics warn that a beat may not prevent selling given the stocks lofty valuation and risk-off sentiment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Iran-related tensions and reported threats to oil shipments through the Strait of Hormuz, which have fueled concerns about supply disruptions and supported crude prices. Bulls see further risk from possible escalation and depleted reserves, while bears expect a sharp pullback if negotiations produce a deal or tensions ease.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Hopes for U.S.-Iran de-escalation are weighing on crude prices and UCO, while persistent concerns about Strait of Hormuz disruptions and constrained supply keep some traders bullish. The community is debating whether diplomacy will ease the oil-risk premium or whether renewed conflict will sustain sharp swings.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Traders are focused on the Iran conflict, Strait of Hormuz shipping risks and reported attacks on energy infrastructure, with concerns about disrupted oil and fuel supply supporting interest in energy stocks. The community is split between those expecting further gains if tensions persist and those warning that diplomacy, easing supply fears or profit-taking could reverse the rally.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion is dominated by the midterm elections and Trumps political fortunes, with traders debating how the outcome could affect DJT and broader markets; speculation over Iran-war escalation and oil prices adds to the uncertainty. Sentiment is mostly bearish, with posts citing DJTs sharp decline and weak fundamentals, though some traders anticipate a rebound.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in TransMedics Group, Inc. (TransMedics or the Company) (NASDAQ: TMDX) for potential breaches of fiduciary duty on the part of its directors and...

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR NewswireANDOVER, Mass., Oct. 30, 2026 ANDOVER, Mass., Oct. 30, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a...

TransMedics to Present at Upcoming Investor Conferences

TransMedics to Present at Upcoming Investor Conferences TransMedics to Present at Upcoming Investor ConferencesPR NewswireANDOVER, Mass., Oct. 29, 2026 ANDOVER, Mass., Oct. 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is...

TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026

TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026 TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026PR NewswireANDOVER, Mass., Oct. 22, 2026 ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX...

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Sept. 26, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no costor...

TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook

TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook PR Newswire ANDOVER, Mass., Sept. 10, 2026 ANDOVER, Mass., Sept. 10, 2026 /PRNewswire...

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Sept. 7, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no cost...

Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?

TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX PR Newswire NEW YORK, Aug...

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Transmedics Group Inc

TMDX Stock Rallies As Analyst Sees 77% Upside  — Here’s Why  

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The firm pointed to growing U.S. transplant activity in heart, liver and lung procedures as a key driver for the company’s Organ Care System (OCS) technology.&nbsp;</li><li>Monthly U.S. transplant data shows heart, liver and lung transplant volumes rose about 5% year-over-year in the second quarter of 2026, according to Cowen.&nbsp;</li><li>In the first quarter of 2026, TransMedics generated $173.9 million in total revenue, representing a 21% increase year-over-year.</li></ul> Shares of TransMedics Group Inc (TMDX) closed up 2% on Wednesday and edged up further after-hours after TD Cowen voiced optimism for the company’s continued revenue expansion in light of the broader growth in the transplant market.TD Cowen maintained its ‘Buy’ rating on TransMedics with a $120 price target, which represents a potential upside of about 77% from the stock’s last close. The firm pointed to growing U.S. transplant activity in heart, liver, and lung procedures as a key driver for the company’s Organ Care System (OCS) technology and its expanding logistics business.<h2 class="st-heading-2">Cowen’s Bullish Thesis On TMDX</h2>TransMedics develops the portable Organ Care System, which preserves and perfuses donor hearts, lungs, and livers outside the body using warm, oxygenated blood. The company also runs a full-service National OCS Program and operates its own aviation logistics network to support faster and more reliable organ transport across the U.S.Monthly U.S. transplant data shows heart, liver, and lung transplant volumes rose about 5% year-over-year in the second quarter of 2026, according to Cowen.Aviation flight data linked to TransMedics’ transplant logistics operations showed even stronger expansion and support for ongoing operational scaling as the company moves beyond its early-stage program launches, it added.<h2 class="st-heading-2">TransMedics Continues To Scale Revenue</h2>In the first quarter of 2026, TransMedics generated $173.9 million in total revenue, representing a 21% increase year-over-year and roughly 8% sequential growth from the previous quarter. Product revenue reached approximately $108 million, while service revenue (largely from its National OCS Program and logistics) contributed about $66 million.The company ended the quarter with a strong cash position of $461.7 million in cash and cash equivalents, down modestly from $488.4 million at the end of 2025, as it continued investing in growth initiatives.<h2 class="st-heading-2">How Did TMDX Retail Traders React?</h2>On Stocktwits, retail sentiment around TMDX stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levelsA Stocktwits user acknowledged the drivers noted by TD Cowen but noted the importance of proper execution, which would determine whether the moment “evolves into a longer-cycle revaluation or remains sentiment-driven.”<stembedurl>https://www.stocktwits.com/GrowthCapitall/message/658048549</stembedurl>According to data from Koyfin, eight of the 11 analysts covering TMDX rate it ‘Buy’ or higher, while three rate it ‘Hold.’ The 12-month average price target on the stock is $117.33, presenting a potential upside of 73% from the stock’s last closing price.<a href="https://stocktwits.com/symbol/TMDX">TMDX stock</a> has fallen 44% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrk-neup-stocks-drop-as-merck-scraps-another-alzheimers-drug-under-neuphoria-partnership/cZm3ANLR711">MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of TransMedics Group Inc. (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, on July 28, 2025. (Photo illustration by Cheng Xin/Getty Images)

TD Cowen maintained its ‘Buy’ rating on TransMedics with a $120 price target. 

iShares Core S&P Small-Cap ETF

Vanguard Total Stock Market ETF

Buying - this is temporary noise

Holding existing position

Selling / Trimming / Shorting

Watching from the sidelines

$TMDX is sliding after Stifel flagged a surge in "dry runs.". TransMedics investors are divided: is this a temporary operational blip or a structural crack in the growth story? Cast your vote below.

$TMDX sliding on &quot;dry run&quot; concerns - are you buying this dip?

Stocktwits

 sliding on "dry run" concerns - are you buying this dip?

Current Price	$65.99
Prev Close	$67.12
Open	$67.59
Dividend Yield	0.00%
50-Day Moving Average	$81.65
Beta	1.27
Avg. Volume	708,637.41
PE Ratio	17.17

52-Week High	$156.00
52-Week Low	$60.11
Market Capitalization	$2.29B
EPS (Annual)	$4.87
Price to Book	4.41
Revenue Per Employee	$674,269.49

Feed

News

Sentiment

Earnings

Fundamentals

Info

TMDX Fundamentals